These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 34595957

  • 21. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.
    Forman R, Long JB, Westvold SJ, Agnish K, Mcmanus HD, Leapman MS, Hurwitz ME, Spees LP, Wheeler SB, Gross CP, Dinan MA.
    JNCI Cancer Spectr; 2024 Sep 02; 8(5):. PubMed ID: 39133171
    [Abstract] [Full Text] [Related]

  • 22. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
    Gatwood J, Dashputre A, Rajpurohit A, Gatwood K, Mackler E, Wallace L, Farris K, Rizvi-Toner A, Farley J.
    J Oncol Pharm Pract; 2024 Mar 02; 30(2):342-353. PubMed ID: 37113049
    [Abstract] [Full Text] [Related]

  • 23. Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence.
    Abughosh SM, Vadhariya A, Johnson ML, Essien EJ, Esse TW, Serna O, Gallardo E, Boklage SH, Choi J, Holstad MM, Fleming ML.
    J Manag Care Spec Pharm; 2019 Oct 02; 25(10):1053-1062. PubMed ID: 31556824
    [Abstract] [Full Text] [Related]

  • 24. A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries.
    Kale HP, Patel AM, Carroll NV.
    J Manag Care Spec Pharm; 2018 Apr 02; 24(4):317-326. PubMed ID: 29578855
    [Abstract] [Full Text] [Related]

  • 25. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
    Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA.
    J Am Geriatr Soc; 2022 Aug 02; 70(8):2330-2343. PubMed ID: 35499667
    [Abstract] [Full Text] [Related]

  • 26. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
    Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P.
    J Manag Care Spec Pharm; 2017 Apr 02; 23(4):461-471. PubMed ID: 28345441
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of a pharmacist-driven medication adherence enhancement service.
    Rinehart SN, Collins C, Glover J, Rice WM.
    J Manag Care Spec Pharm; 2021 Apr 02; 27(4):507-515. PubMed ID: 33769859
    [Abstract] [Full Text] [Related]

  • 28. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications.
    Majd Z, Mohan A, Paranjpe R, Abughosh SM.
    J Manag Care Spec Pharm; 2021 Feb 02; 27(2):186-197. PubMed ID: 33506725
    [Abstract] [Full Text] [Related]

  • 29. Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan.
    Wang X, Chen H, Essien E, Wu J, Serna O, Paranjpe R, Abughosh S.
    J Manag Care Spec Pharm; 2019 Jun 02; 25(6):678-686. PubMed ID: 31134857
    [Abstract] [Full Text] [Related]

  • 30. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
    Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA.
    Cancer Med; 2021 Oct 02; 10(19):6653-6665. PubMed ID: 34480518
    [Abstract] [Full Text] [Related]

  • 31. Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure.
    Steve Tsang CC, Browning J, Todor L, Dougherty S, Hohmeier KC, Sam Li M, Borja-Hart N, Hines LE, Wang J.
    J Manag Care Spec Pharm; 2021 Aug 02; 27(8):971-981. PubMed ID: 34337985
    [Abstract] [Full Text] [Related]

  • 32. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J, Reddy SR, Chang E, Broder MS, Gokhale S, Corral M.
    J Manag Care Spec Pharm; 2021 Dec 02; 27(12):1724-1733. PubMed ID: 34818092
    [Abstract] [Full Text] [Related]

  • 33. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN, Keating NL, Dusetzina SB.
    J Clin Oncol; 2016 Dec 20; 34(36):4323-4328. PubMed ID: 27998234
    [Abstract] [Full Text] [Related]

  • 34. Disparities in Initial Oral Antidiabetic Medication Adherence Among Veterans with Incident Diabetes.
    Gatwood JD, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, Kovesdy CP.
    J Manag Care Spec Pharm; 2018 Apr 20; 24(4):379-389. PubMed ID: 29578849
    [Abstract] [Full Text] [Related]

  • 35. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
    Hutson TE, Liu FX, Dieyi C, Kim R, Krulewicz S, Kasturi V, Bhanegaonkar A.
    J Manag Care Spec Pharm; 2021 Sep 20; 27(9):1171-1181. PubMed ID: 34165322
    [Abstract] [Full Text] [Related]

  • 36. Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System.
    Hui RL, Adams AL, Niu F, Ettinger B, Yi DK, Chandra M, Lo JC.
    J Manag Care Spec Pharm; 2017 Apr 20; 23(4):503-512. PubMed ID: 28345435
    [Abstract] [Full Text] [Related]

  • 37. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C, Axon DR, Mollon L, Taylor AM, Pickering M, Black H, Warholak T, Campbell PJ.
    J Manag Care Spec Pharm; 2021 Jan 20; 27(1):64-72. PubMed ID: 33377445
    [Abstract] [Full Text] [Related]

  • 38. Patterns of Long-Term Prescription Opioid Use Among Older Adults in the United States: A Study of Medicare Administrative Claims Data.
    Ramachandran S, Salkar M, Bentley JP, Eriator I, Yang Y.
    Pain Physician; 2021 Jan 20; 24(1):31-40. PubMed ID: 33400426
    [Abstract] [Full Text] [Related]

  • 39. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A, Yost C, Squires P, Raju A, Schroader B, Brown JD.
    J Manag Care Spec Pharm; 2021 May 20; 27(5):554-564. PubMed ID: 33908275
    [Abstract] [Full Text] [Related]

  • 40. Treatment Patterns and Characteristics of Individuals Initiating High-Dose Insulin for Type 2 Diabetes Mellitus.
    Chen J, Nair R, Siadaty M, Brown K, Meah Y, Taylor AD, He X, Fan L.
    J Manag Care Spec Pharm; 2020 Jul 20; 26(7):839-847. PubMed ID: 32584684
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.